554 related articles for article (PubMed ID: 15774572)
1. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
Katzmann JA; Abraham RS; Dispenzieri A; Lust JA; Kyle RA
Clin Chem; 2005 May; 51(5):878-81. PubMed ID: 15774572
[TBL] [Abstract][Full Text] [Related]
2. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
3. Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies.
Wood PB; McElroy YG; Stone MJ
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):278-80. PubMed ID: 20709664
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
Wolff F; Thiry C; Willems D
Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
[TBL] [Abstract][Full Text] [Related]
5. Serum free light chains in clinical laboratory diagnostics.
Jenner E
Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
[TBL] [Abstract][Full Text] [Related]
6. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
8. Urine immunofixation electrophoresis remains important and is complementary to serum free light chain.
Levinson SS
Clin Chem Lab Med; 2011 Nov; 49(11):1801-4. PubMed ID: 21663562
[TBL] [Abstract][Full Text] [Related]
9. Screening panels for detection of monoclonal gammopathies.
Katzmann JA; Kyle RA; Benson J; Larson DR; Snyder MR; Lust JA; Rajkumar SV; Dispenzieri A
Clin Chem; 2009 Aug; 55(8):1517-22. PubMed ID: 19520758
[TBL] [Abstract][Full Text] [Related]
10. Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies: High False-Positive Rate.
Singh G
Am J Clin Pathol; 2016 Aug; 146(2):207-14. PubMed ID: 27473738
[TBL] [Abstract][Full Text] [Related]
11. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.
Campbell JP; Cobbold M; Wang Y; Goodall M; Bonney SL; Chamba A; Birtwistle J; Plant T; Afzal Z; Jefferis R; Drayson MT
J Immunol Methods; 2013 May; 391(1-2):1-13. PubMed ID: 23388695
[TBL] [Abstract][Full Text] [Related]
12. Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies.
Eckold J; Poenisch W; Drogies T; Kratzsch J; Teupser D; Thiery J; Bruegel M
Clin Lab; 2014; 60(9):1491-500. PubMed ID: 25291945
[TBL] [Abstract][Full Text] [Related]
13. Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory.
Caponi L; Romiti N; Koni E; Fiore AD; Paolicchi A; Franzini M
Crit Rev Clin Lab Sci; 2020 Mar; 57(2):73-85. PubMed ID: 31612753
[TBL] [Abstract][Full Text] [Related]
14. Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry.
Sepiashvili L; Kohlhagen MC; Snyder MR; Willrich MAV; Mills JR; Dispenzieri A; Murray DL
Clin Chem; 2019 Aug; 65(8):1015-1022. PubMed ID: 31171529
[TBL] [Abstract][Full Text] [Related]
15. Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders.
Vermeersch P; Vercammen M; Holvoet A; Vande Broek I; Delforge M; Bossuyt X
Clin Chim Acta; 2009 Dec; 410(1-2):54-8. PubMed ID: 19778527
[TBL] [Abstract][Full Text] [Related]
16. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
Akar H; Seldin DC; Magnani B; O'Hara C; Berk JL; Schoonmaker C; Cabral H; Dember LM; Sanchorawala V; Connors LH; Falk RH; Skinner M
Amyloid; 2005 Dec; 12(4):210-5. PubMed ID: 16399645
[TBL] [Abstract][Full Text] [Related]
17. Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population.
Abadie JM; Bankson DD
Ann Clin Lab Sci; 2006; 36(2):157-62. PubMed ID: 16682511
[TBL] [Abstract][Full Text] [Related]
18. Application of Capillary Electrophoresis in Monoclonal Gammopathies and the Cutoff Value of Monoclonal Protein in Differential Diagnosis of Multiple Myeloma and Other Monoclonal Gammopathies.
Cao F; Zhang R; Xu L; Liu M; Yuan Y
Ann Clin Lab Sci; 2021 May; 51(3):400-407. PubMed ID: 34162571
[TBL] [Abstract][Full Text] [Related]
19. Strengths and weaknesses of methods for identifying monoclonal free light chains of Ig: examples from two cases with renal disease.
Levinson SS
Clin Chem Lab Med; 2016 Jun; 54(6):1039-43. PubMed ID: 26368046
[TBL] [Abstract][Full Text] [Related]
20. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies.
Hill PG; Forsyth JM; Rai B; Mayne S
Clin Chem; 2006 Sep; 52(9):1743-8. PubMed ID: 16858075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
